Furthermore, the potential for combining ALDH1A3 inhibition with existing immune checkpoint inhibition therapy or senescent cell purgants to improve tumor patient prognosis needs to be verified through further cell, animal, and clinical studies. This evidence concerns the gene ALDH1A3 and neoplasm.